VIVUS — Technical Presentation (June 2011)
5 slides from VIVUS's technical presentation, Jun 17, 2011
Slide 1: Avanafil Post-Prostatectomy Erectile Dysfunction Study Poster: Introduction, Objectives, Methods
Below is a reproduction of the contents of the poster entitled “A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Safety and Efficacy of Avanafil in the Treatment of Erectile Dysfunction Following Bilateral, Nerve-Sparing Radical Prostatectomy”: John P. Mulhall
Slide 2: Figure 1. Successful Vaginal Penetration (SEP 2; ITT)
Figure 1. Successful Vaginal Penetration (SEP 2; ITT). Mean Percentage 38 $s Ha 32 SE 3 100 (n= *P001 va placebo Mi sacctne Ena of vearment
Slide 3: Figure 2. Successful Intercourse Attempts (SEP 3; ITT)
‘igure 2. Successful Intercourse Attempts (SEP 3; ITT).
Slide 4: Successful Intercourse by Postdose Time Interval
Successful Intercourse by Postdose Time Interval · In total, 82.4% of sexual attempts studywide were made within 60 minutes or less. · One-third to one-half of all intercourse attempted at < 15 minutes and < 30 minutes was successful across both avanafil treatment groups (Figure 4).
Slide 5: Safety Summary
Safety Summary · Discontinuations or interruptions of study drug due to adverse events (AEs) were 3%, 3%, and 2% for placebo, 100 mg, and 200 mg, respectively (Table 2). · There were no serious AEs and no deaths during the study Table 2. Summary of Adverse Events (Safety Population). Subjects With A